23andMe Launches Health Action Plan to Provide Personalized Recommendations Based on Genetic and Other Health Data
31 Outubro 2023 - 9:00AM
23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading genetic
health and biopharmaceutical company, today launched Health Action
Plan, a new digital tool for 23andMe+ members that draws on results
from genetic reports, health history survey data, as well as blood
and biomarker data to provide a uniquely tailored set of health
recommendations out of hundreds of options.
In addition to suggestions on altering activities like sleep,
diet, and exercise, other recommendations include learning about
potential new treatments or activities for conditions, as well as
entering additional health data, like diagnoses or family history,
to further personalize recommendations. Eligible customers may also
receive recommendations for further clinical action, like getting a
blood test, which can now be coordinated directly through 23andMe.
Testing managed through the 23andMe platform provides a fast and
convenient way to order, pay, and schedule an appointment at a
local lab, and receive results and a personalized clinical analysis
in 3-5 business days.* The biomarker data, in addition to genetic
data, can help identify possible health risks for individuals to
take any necessary actions. Customers can also connect with a
clinician to discuss their results.
“Health Action Plan is a powerful tool for customers, combining
genetic and non-genetic data, along with lab testing to tailor
health recommendations,” said Robin Smith, Ph.D., Director of
Product Management at 23andMe. “This feature provides customers
with a prioritized to-do list of recommendations based on their DNA
that's updated as new reports are released or additional scientific
discoveries are made.”
Health Action Plan is a helpful first step when it comes to
prevention and early risk detection. It offers customers specific
actions and next steps on their health journey. Each recommendation
is evidence-based, and written and reviewed by a team of
scientists, genetic counselors, and medical experts at 23andMe. The
new digital tool draws on a customer's genetic health reports and
their self-reported health history. Together, this data helps
inform tailored recommendations, prioritizing the most critical
steps for an individual to take. The more information a customer
provides, the more personalized their recommendations will
become.
For example, if a customer’s Triglycerides report (Powered by
23andMe Research) indicates an increased likelihood for developing
high triglycerides, a recommendation might be to get a blood test
that looks at triglycerides and other lipids. This is important
because high triglycerides often have no symptoms, and can be a
risk factor not just for heart disease, but also a group of
conditions called metabolic syndrome. Metabolic syndrome increases
the risk for serious conditions like heart disease and stroke.
For individuals with an increased likelihood for developing high
triglycerides or who have high triglycerides or other lipids, there
are steps one can take including changes in diet and lifestyle that
could help.
23andMe reminds customers that they should not use Health Action
Plan to replace a visit to their primary healthcare provider.
*Blood testing through 23andMe is not
available in NY, NJ, RI, OK, HI, PR
About 23andMe 23andMe is a genetics-led
consumer healthcare and biopharmaceutical company empowering a
healthier future. For more information, please visit
www.23andMe.com.
Forward-Looking StatementsThis press release
contains forward-looking statements within the meaning of Section
27A of the Securities Act of 1933, as amended, and Section 21E of
the Securities Exchange Act of 1934, as amended, including, without
limitation, statements regarding the future performance of
23andMe's businesses in consumer genetics and therapeutics and the
growth and potential of its proprietary research platform. All
statements, other than statements of historical fact, included or
incorporated in this press release, including statements regarding
23andMe's products, plans, product development and launches, the
successful commercialization and market acceptance of new products
and objectives of management, are forward-looking statements. The
words "believes," "anticipates," "estimates," "plans," "expects,"
"intends," "may," "could," "should," "potential," "likely,"
"projects," "predicts," "continue," "will," "schedule," and "would"
or, in each case, their negative or other variations or comparable
terminology, are intended to identify forward-looking statements,
although not all forward-looking statements contain these
identifying words. These forward-looking statements are predictions
based on 23andMe's current expectations and projections about
future events and various assumptions. 23andMe cannot guarantee
that it will actually achieve the plans, intentions, or
expectations disclosed in its forward-looking statements and you
should not place undue reliance on 23andMe's forward-looking
statements. These forward-looking statements involve a number of
risks, uncertainties (many of which are beyond the control of
23andMe), or other assumptions that may cause actual results or
performance to differ materially from those expressed or implied by
these forward-looking statements. The forward-looking statements
contained herein are also subject generally to other risks and
uncertainties that are described from time to time in the Company's
filings with the Securities and Exchange Commission, including
under Item 1A, "Risk Factors" in the Company's most recent Annual
Report on Form 10-K, as filed with the Securities and Exchange
Commission, and as revised and updated by our Quarterly Reports on
Form 10-Q and Current Reports on Form 8-K. The statements made
herein are made as of the date of this press release and, except as
may be required by law, 23andMe undertakes no obligation to update
them, whether as a result of new information, developments, or
otherwise.
ContactsInvestor Relations Contact:
investors@23andMe.comMedia Contact: press@23andMe.com
23andMe (NASDAQ:ME)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
23andMe (NASDAQ:ME)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024